These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 11365623)

  • 21. [Study on the indeterminate results of characterization and verification of HIV antibody from Western blot test].
    Bao ZY; Liu YJ; Wang HY; Wang QL; Luo Q; Liu YD; Ma F; Xing YC; Tong YG; Li JY
    Zhonghua Liu Xing Bing Xue Za Zhi; 2008 May; 29(5):478-81. PubMed ID: 18956682
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Tuberculosis in compromised hosts].
    Kekkaku; 2003 Nov; 78(11):717-22. PubMed ID: 14672050
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The rate of serious bacterial infections among HIV-infected children with immune reconstitution who have discontinued opportunistic infection prophylaxis.
    Nachman S; Gona P; Dankner W; Weinberg A; Yogev R; Gershon A; Rathore M; Read JS; Huang S; Elgie C; Hudgens K; Hughes W
    Pediatrics; 2005 Apr; 115(4):e488-94. PubMed ID: 15772172
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Administration of live varicella vaccine to HIV-infected children with current or past significant depression of CD4(+) T cells.
    Levin MJ; Gershon AA; Weinberg A; Song LY; Fentin T; Nowak B;
    J Infect Dis; 2006 Jul; 194(2):247-55. PubMed ID: 16779732
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Delayed progression to AIDS in volunteers treated with long-term HIV-1 Immunogen (REMUNE) therapy in Thailand.
    Chantratita W; Sukeepaisarncharoen W; Chandeying V; Kulpradist S; Israngkura Na Ayudhtaya B; Rugpao S; Sirawaraporn W; Boonshuyar C; Churdboonchart V
    HIV Med; 2004 Sep; 5(5):317-25. PubMed ID: 15369506
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antiviral activity of low-dose alovudine in antiretroviral-experienced patients: results from a 4-week randomized, double-blind, placebo-controlled dose-ranging trial.
    Ghosn J; Quinson AM; Sabo N; Cotte L; Piketty C; Dorléacq N; Bravo ML; Mayers D; Harmenberg J; Mårdh G; Valdez H; Katlama C
    HIV Med; 2007 Apr; 8(3):142-7. PubMed ID: 17461857
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and immunogenicity of an inactivated hepatitis A vaccine among HIV-infected subjects.
    Wallace MR; Brandt CJ; Earhart KC; Kuter BJ; Grosso AD; Lakkis H; Tasker SA
    Clin Infect Dis; 2004 Oct; 39(8):1207-13. PubMed ID: 15486846
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Improvement in immune parameters and human immunodeficiency virus-1 viral response in individuals treated with 16alpha-bromoepiandrosterone (HE2000).
    Reading C; Dowding C; Schramm B; Garsd A; Onizuka-Handa N; Stickney D; Frincke J
    Clin Microbiol Infect; 2006 Nov; 12(11):1082-8. PubMed ID: 17002607
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Seroreversion in subjects receiving antiretroviral therapy during acute/early HIV infection.
    Hare CB; Pappalardo BL; Busch MP; Karlsson AC; Phelps BH; Alexander SS; Bentsen C; Ramstead CA; Nixon DF; Levy JA; Hecht FM
    Clin Infect Dis; 2006 Mar; 42(5):700-8. PubMed ID: 16447118
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Women, HIV & viral load.
    Denison R
    WORLD; 1999 Apr; (No 96):4-5. PubMed ID: 11366945
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [One antibody preparation is not another: the role of passive immunotherapy in the treatment of HIV infection].
    Leverstein-van Hall MA; Goudsmit J
    Ned Tijdschr Geneeskd; 1995 Feb; 139(7):316-20. PubMed ID: 7877699
    [No Abstract]   [Full Text] [Related]  

  • 32. [The prognostic value of virology and immunology markers in Chinese HIV-1 infected people].
    Lin X; Xu L; Shao Y
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 1999 Mar; 13(1):41-4. PubMed ID: 12759951
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of GB virus C on response to antiretroviral therapy in HIV-infected Brazilians.
    Souza IE; Zhang W; Diaz RS; Chaloner K; Klinzman D; Stapleton JT
    HIV Med; 2006 Jan; 7(1):25-31. PubMed ID: 16313289
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Characterization of GBV-C infection in HIV-1 infected patients.
    Canducci F; Uberti Foppa C; Boeri E; Racca S; Gallotta G; Grasso MA; Calori G; Lazzarin A; Clementi M
    J Biol Regul Homeost Agents; 2003; 17(2):191-4. PubMed ID: 14518722
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Highly Active AntiRetroviral Therapy and opportunistic protozoan infections].
    Pozio E
    Parassitologia; 2004 Jun; 46(1-2):89-93. PubMed ID: 15305694
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Virological and immunological data of AIDS patients treated by passive immunotherapy (transfusions of plasma rich in HIV-1 antibodies).
    Morand-Joubert L; Vittecoq D; Roudot-Thoraval F; Mariotti M; Lefrère F; Heshmati F; Audat F; Lambin P; Barré-Sinoussi F; Lefrère JJ
    Vox Sang; 1997; 73(3):149-54. PubMed ID: 9358616
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combination antibody treatment controls HIV infection in phase 1 trial.
    Harper KN
    AIDS; 2019 Mar; 33(3):N3-N4. PubMed ID: 30585848
    [No Abstract]   [Full Text] [Related]  

  • 39. [One antibody preparation is not the other: the role of passive immunotherapy in the treatment of HIV infections].
    Laane HM
    Ned Tijdschr Geneeskd; 1995 Apr; 139(16):850-1. PubMed ID: 7731480
    [No Abstract]   [Full Text] [Related]  

  • 40. Passive hyperimmune therapy: buying time at what cost?
    Chavez C
    Caring; 1996 Aug; 15(8):48-50. PubMed ID: 10159954
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.